- Investing Ideas
- /
- Swiss Pharmaceuticals & Biotech Potentially Undervalued Companies
Swiss Pharmaceuticals & Biotech Potentially Undervalued Companies
UPDATED Jul 03, 2022
Companies with a Value score of at least 3, ordered by Value score
33 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| NOVNNovartis | CHF80.33 | -0.3% | -5.0% | CHF174.5b | CHF91.19 | PE7.5x | E2.8% | 3.7% | ||
| TECNTecan Group | CHF285.80 | -0.4% | -38.9% | CHF3.6b | CHF494.33 | PE29.9x | E13.0% | 1.0% | ||
| QGENQiagen | US$48.85 | 0% | 17.9% | US$10.9b | US$57.50 | PE20.2x | E7.0% | n/a | ||
| 935700Gilead Sciences | US$55.82 | 0% | -25.6% | US$78.2b | US$62.34 | PE17.3x | E8.3% | 4.7% | ||
| 1102657GSK | UK£21.42 | 0% | -0.4% | UK£90.4b | UK£22.42 | PE17.7x | E10.4% | 4.5% | ||
| ESFEurofins Scientific | €505.00 | 0% | 0.08% | €14.5b | €691.99 | PE19.3x | E-0.2% | 1.3% | ||
| 907582Amgen | US$227.36 | 0% | 26.4% | US$131.2b | US$228.25 | PE22.9x | E9.7% | 3.2% | ||
| COPNCosmo Pharmaceuticals | CHF46.70 | 1.5% | -45.2% | CHF780.2m | CHF85.90 | PE36x | E46.7% | 2.0% | ||
| MOLNMolecular Partners | CHF6.59 | -7.2% | -64.7% | CHF214.2m | CHF26.81 | PE2x | E-74.0% | n/a | ||
| BIIBBiogen | US$220.00 | 0% | 0% | US$30.8b | US$253.58 | PE21.3x | E2.3% | n/a | ||
| SFZNSiegfried Holding | CHF624.50 | -0.2% | -28.7% | CHF2.7b | CHF861.03 | PE27.7x | E12.0% | 0.5% | ||
| 10683053Merck | US$87.25 | -1.1% | 5.6% | US$233.7b | US$91.19 | PE16.8x | E11.8% | 3.0% | ||
| NOVNEENovartis | CHF80.23 | -0.3% | -6.1% | CHF174.5b | CHF91.07 | PE7.5x | E2.8% | 3.7% | ||
| NWRNNewron Pharmaceuticals | CHF1.45 | -5.2% | -43.1% | CHF25.9m | CHF9.25 | PS4.5x | E54.6% | n/a | ||
| TEVATeva Pharmaceutical Industries | US$7.85 | 0% | 0% | US$8.8b | US$9.84 | PB0.9x | E105.1% | 0% | ||
| GXIGerresheimer | €75.60 | 0% | 0% | €1.8b | €119.42 | PE21.3x | E20.9% | 2.2% | ||
| RORoche Holding | CHF372.00 | 2.8% | -2.0% | CHF262.0b | CHF448.47 | PE18.4x | E7.4% | 2.9% | ||
| ROGRoche Holding | CHF320.40 | 0.5% | -8.3% | CHF262.0b | CHF386.26 | PE18.4x | E7.4% | 2.9% | ||
| 943981Johnson & Johnson | US$170.06 | 0% | 21.5% | US$472.4b | US$177.41 | PE23.8x | E4.4% | 2.5% | ||
| BMYBristol-Myers Squibb | US$54.24 | 0% | 22.2% | US$163.6b | US$55.80 | PE26.2x | E14.0% | 2.8% | ||
| UNCUCB | €111.21 | 0% | n/a | €15.6b | €147.29 | PE14.8x | E9.5% | 1.6% | ||
| 982352AstraZeneca | UK£117.49 | 0% | 23.7% | UK£166.6b | UK£129.35 | PS4.8x | E27.5% | 2.0% | ||
| VRXBausch Health Companies | US$24.11 | 0% | 0% | US$3.1b | US$76.60 | PE-7.6x | E48.2% | 0% | ||
| WBIOWockhardt Bio | CHF1.58 | 17.0% | n/a | CHF82.1m | n/a | PE2.3x | n/a | 0% |